Table 2.
CWA-APTT in patients with malignant neoplasm.
| 2nd DPT | 1st DPT | FFT | 2nd DPH | 1st DPH | FFH | |
|---|---|---|---|---|---|---|
| Cancer Type | Seconds | mm Absorbance | ||||
| Hepatocellular carcinoma | 32.7 (26.8–42.0) |
35.2 (28.9–46.1) |
38.2 (31.1–53.4) |
883 ** (264–1981) |
283 * (139–801) |
250 *** (164–759) |
| Colon cancer | 33.5 (31.2–39.3) |
36.7 (33.8–42.7) |
40.4 (36.2–45.9) |
1235 ** (1024–1452) |
460 ** (330–509) |
387 ** (286–447) |
| Stomach cancer | 34.7 (28.7–38.5) |
37.5 (31.5–42.4) |
40.0 (34.0–49.5) * |
773 (450–1278) |
307 * (147–457) |
279 *** (172–480) |
| Prostate cancer | 34.8 (29.5–60.7) |
37.7 (32.2–65.4) |
39.9 (34.4–67.8) |
810 (647–1220) |
317 ** (254–427) |
296 ** (214–330) |
| Biliary tract cancer | 34.0 * (25.7–48.3) |
37.0 * (28.0–58.8) |
40.6 * (30.5–62.7) |
784 (151–1789) |
315 (90.7–544) |
257 *** (221–621) |
| Lung cancer | 34.0 (29.9–40.3) |
36.6 (32.3–45.1) |
39.5 (34.2–49.5) |
752 (443–1004) |
259 (132–450) |
224 * (178–480) |
| Pancreatic cancer | 35.2 *** (32.6–39.3) |
38.5 *** (36.2–42.8) |
41.4 *** (38.1–48.2) |
973 * (302–1422) |
353 ** (254–559) |
336 *** (172–489) |
| Esophageal cancer | 37.9 (31.4–44.7) |
42.6 (34.1–50.0) |
44.8 * (36.9–51.9) |
1215 ** (972–1572) |
491 ** (418–595) |
448 ** (317–477) |
| malignant lymphoma | 36.1 * (28.0–56.2) |
39.7 * (30.5–60.5) |
43.9 ** (32.5–68.7) |
863 (274–1361) |
311 ** (157–577) |
323 *** (195–634) |
| Myelodysplastic syndrome | 37.5 *** (31.5–78.5) |
40.0 ** (34.1–88.5) |
46.9 ** (35.8–90.3) |
712 (128–1144) |
337 (157–577) |
256 *** (182–653) |
| Others | 38.1 (31.1–44.5) |
43.3 * (33.8–52.1) |
44.9 * (35.8–55.6) |
845 (596–1246) |
328 (187–552) |
319 (163–738) |
| Healthy volunteers | 31.7 (29.6–35.7) |
34.3 (32.1–39.7) |
36.0 (34.0–41.1) |
734 (453–975) |
235 (137–316) |
187 (131–256) |
Data are shown as the median (range). CWA-APTT, clot waveform analysis-activated partial thromboplastin time; DPT, derivative peak time; DPH, derivative peak height; FFT, fibrin formation time; FFH, fibrin formation height; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to healthy volunteers.